Bioxyne to Manufacture Medical Cannabis Products for Aurora Cannabis

SYDNEY – In a development that highlights the growing emphasis on dependable supply chains across the medical Cannabis sector, Bioxyne Limited has secured a manufacturing agreement with Aurora Cannabis Inc. to produce pharmaceutical-grade medicinal Cannabis products for select regulated markets worldwide.

The deal involves Bioxyne’s wholly owned subsidiary Breathe Life Sciences, a GMP-licensed operation based in Australia. Initial production centers on medicinal Cannabis oils for the Australian market, with the first deliveries already completed. The scope is set to widen to GMP-manufactured cannabis vapes headed for Australia, the United Kingdom and Germany, with further product lines under discussion.

Purchase orders received so far cover more than 5,000 units of sublingual oils and over 20,000 vapes, plus two gummy-style pastille stock-keeping units for Australia and the U.K. Bioxyne projects the relationship will generate $3 million to $5 million in manufacturing value during the next 12 months as volumes grow. The agreement runs on a 12-month rolling term with automatic renewal and can be ended with six months’ notice. It does not alter Bioxyne’s prior market guidance.

Sam Watson, Bioxyne’s CEO, described the arrangement as a step forward for the company’s manufacturing reach. Alex Miller, Aurora’s executive vice president for operations and supply chain, noted that the partnership fits the Canadian firm’s effort to maintain a reliable, high-quality global network.

Aurora ranks among the world’s largest medical Cannabis producers and has long emphasized supply-chain resilience across borders. Bioxyne, with operations in Japan, the U.K. and Europe, brings TGA-compliant GMP facilities that meet stringent standards accepted in multiple jurisdictions. The contract-manufacturing model lets Aurora tap existing capacity without new capital outlays, while giving Bioxyne a larger role in international production.

The arrangement arrives as medical Cannabis programs expand in Australia, the U.K. and Germany, where consistent dosing and regulatory compliance remain central concerns for both producers and patients. For a smaller manufacturer like Bioxyne, the tie-up with a major global name offers validation of its technical standards and a pathway to larger-scale output. The financial contribution, though incremental, comes without shifting the company’s overall forecasts, suggesting a measured addition to its base business.